| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione does not have a defined biological target as a standalone compound; it is a synthetic intermediate for the preparation of steroidal compounds. Its parent compounds and derivatives, such as Vamorolone and various fluorinated corticosteroids, target the glucocorticoid receptor and exhibit anti-inflammatory activity. The compound's role in the synthesis of delta-9,11 steroids makes it a valuable intermediate for the production of glucocorticoid analogs with modified pharmacological properties.
|
|---|---|
| ln Vitro |
Instead of having the negative effects of conventional corticosteroids, Δ9,11 derivatives are made to stably integrate into cell membranes and reduce lipid peroxidation without glucocorticoid or mineralocorticoid activities[1]. Due to its strong NF-κB inhibition, GR translocation that is comparable to that of prednisone and dexamethasone, lack of transactivation characteristics, and high bioavailability, VBP15 functions as a lead compound[1].
As a synthetic intermediate, 21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione does not have intrinsic in vitro biological activity that is characterized for pharmacological purposes. Its derivatives, such as Vamorolone and fluorinated corticosteroids, exhibit anti-inflammatory activity through glucocorticoid receptor activation. The compound is used in chemical synthesis to produce these active pharmaceutical ingredients. Its chemical properties and reactivity are characterized for synthetic applications rather than biological activity. |
| ln Vivo |
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is not used for in vivo pharmacological activity assessment as a standalone compound. It is a synthetic intermediate used in the production of delta-9,11 steroids such as Vamorolone and fluorinated corticosteroids. These derivatives, once synthesized, are evaluated for their anti-inflammatory activity and other pharmacological properties in vivo. The compound itself is not administered to animals for pharmacological studies.
|
| Enzyme Assay |
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is not used in enzyme/receptor binding assays as a test compound. It is a synthetic intermediate used in chemical synthesis. The derivatives produced from this intermediate, such as Vamorolone and fluorinated corticosteroids, are assessed for binding affinity to the glucocorticoid receptor using competitive binding assays. These assays evaluate the pharmacological activity of the final compounds rather than the intermediate itself.
|
| Cell Assay |
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is not used in cell-based assays as a test compound. It is a synthetic intermediate used in the chemical synthesis of steroidal compounds. The derivatives produced from this intermediate, such as Vamorolone and fluorinated corticosteroids, are evaluated in cell-based assays for their anti-inflammatory and other pharmacological activities. These assays assess the biological activity of the final compounds rather than the intermediate.
|
| Animal Protocol |
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is not used in animal studies as a pharmacological agent. It is a synthetic intermediate used in the production of steroidal compounds. The derivatives produced from this intermediate, such as Vamorolone and fluorinated corticosteroids, are evaluated in animal models for their anti-inflammatory and other pharmacological activities. These studies assess the in vivo efficacy and safety of the final compounds rather than the intermediate.
|
| ADME/Pharmacokinetics |
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione has a molecular weight of 366.45 g/mol and a molecular formula of C₂₃H₂₆O₄. It is a steroidal compound belonging to the pregnane class. The compound is an intermediate in the synthesis of delta-9,11 steroids, such as Vamorolone. Its role as a key intermediate in the synthesis of highly active fluorinated corticosteroids makes it valuable for pharmaceutical research. The compound is typically stored under conditions recommended for synthetic intermediates.
|
| Toxicity/Toxicokinetics |
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione is intended for research use as a synthetic intermediate and is not approved for human therapeutic applications. As a chemical intermediate, comprehensive toxicological data are not available for this compound. Standard laboratory safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| References | |
| Additional Infomation |
21-Acetoxypregna-1,4,9(11),16-tetraene-3,20-dione (CAS#: 37413-91-5) has a molecular formula of C₂₃H₂₆O₄ and a molecular weight of 366.45 g/mol. It is also known as tetraene acetate. It is a steroidal compound belonging to the pregnane class. This compound is an intermediate in the synthesis of delta-9,11 steroids such as Vamorolone. Delta-9,11 steroids are modified glucocorticoids with anti-inflammatory activity. It is a key intermediate in the synthesis of highly active fluorinated corticosteroids. This compound is not a drug and is strictly a synthetic intermediate.
|
| Molecular Formula |
C23H26O4
|
|---|---|
| Molecular Weight |
366.45
|
| Exact Mass |
366.183
|
| CAS # |
37413-91-5
|
| PubChem CID |
10926647
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
534.6±50.0 °C at 760 mmHg
|
| Flash Point |
233.0±30.2 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.585
|
| LogP |
3.48
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
27
|
| Complexity |
856
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC(=O)OCC(=O)C1=CC[C@@H]2[C@@]1(CC=C3[C@H]2CCC4=CC(=O)C=C[C@@]43C)C
|
| InChi Key |
UFEOMHFPJREVTP-PTRHGPIFSA-N
|
| InChi Code |
InChI=1S/C23H26O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h7-10,12,17-18H,4-6,11,13H2,1-3H3/t17-,18-,22-,23-/m0/s1
|
| Chemical Name |
[2-[(8S,10S,13S,14S)-10,13-dimethyl-3-oxo-6,7,8,12,14,15-hexahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (272.89 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7289 mL | 13.6444 mL | 27.2889 mL | |
| 5 mM | 0.5458 mL | 2.7289 mL | 5.4578 mL | |
| 10 mM | 0.2729 mL | 1.3644 mL | 2.7289 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
